The test will be developed in Global Good labs and ported onto QuantuMDx's handheld molecular platform.
In Nature this week: Plasmodium genomes and evolution, novel developmental disorder loci, and more.
The Cancer Genome Atlas Research Network team uncovered new mutations and amplifications in their cohort of primary cervical cancers.
The firms will target 18 Latin American countries in three years, with the goal of creating a complete HPV diagnostics system for the region.
The firm is also pursuing ovarian cancer screening and head and neck cancer tests using methylation-specific PCR.
The firm's PCR-based products for HPV-associated cancers look at DNA methylation at specific genes and include several sample preparation kits.
An evaluation of more than 5,000 women attending primary cervical cancer screening showed self-collection and physician-collected samples are comparable.
The UK firm anticipates CE marking shortly and will focus on the European and Chinese markets for its multiplex PCR test for human papillomavirus genotyping.
The company's Confidence assays are designed to detect if a woman has a high-risk HPV subtype and, if so, determine her risk of developing cervical pre-cancer or cancer.
The agreement covers GynTect, which uses epigenetic biomarkers and methylation-specific PCR to determine if an HPV-positive patient is at risk for developing cervical cancer.
In Science this week: genetic target for urothelial bladder cancer treatment, and more.
At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.
Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.
Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.